Nothing Special   »   [go: up one dir, main page]

WO2018088813A3 - Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 - Google Patents

Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 Download PDF

Info

Publication number
WO2018088813A3
WO2018088813A3 PCT/KR2017/012651 KR2017012651W WO2018088813A3 WO 2018088813 A3 WO2018088813 A3 WO 2018088813A3 KR 2017012651 W KR2017012651 W KR 2017012651W WO 2018088813 A3 WO2018088813 A3 WO 2018088813A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragment
pharmaceutical composition
active ingredient
same
arthritis
Prior art date
Application number
PCT/KR2017/012651
Other languages
English (en)
French (fr)
Other versions
WO2018088813A9 (ko
WO2018088813A2 (ko
Inventor
김대원
Original Assignee
아이씨엠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2019545223A priority Critical patent/JP6991593B2/ja
Priority to CN201780069569.5A priority patent/CN110036023B/zh
Priority to US16/348,540 priority patent/US11235025B2/en
Priority to CA3042186A priority patent/CA3042186C/en
Priority to CN202211029784.1A priority patent/CN115925865A/zh
Priority to EP17868981.6A priority patent/EP3539978B1/en
Application filed by 아이씨엠 주식회사 filed Critical 아이씨엠 주식회사
Priority to EP21154441.6A priority patent/EP3835311B1/en
Priority to AU2017358282A priority patent/AU2017358282C1/en
Publication of WO2018088813A2 publication Critical patent/WO2018088813A2/ko
Publication of WO2018088813A3 publication Critical patent/WO2018088813A3/ko
Publication of WO2018088813A9 publication Critical patent/WO2018088813A9/ko
Priority to US16/805,370 priority patent/US11154590B2/en
Priority to AU2020207879A priority patent/AU2020207879B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 관절염의 병리조직 환경 하에서 안정성이 향상된 Nkx3.2의 단편 및 이를 유효성분으로 함유하는 약학 조성물에 관한 것이다. 본 발명의 Nkx3.2 단편은 전장의 Nkx3.2와 유사한 수준의 NF-κB 활성화 기능을 가지며, Siah1에 의한 단백질 분해에 저항성을 가진다. 또한, 상기 Nkx3.2 단편은 동물모델 기반 in vivo 효능 평가에서 Nkx3.2에 비해 최소 10배 이상 향상된 퇴행성 관절염 치료효과를 나타내었다. 따라서, 상기 Nkx3.2 단편은 관절염 예방 또는 치료에 유용하게 사용할 수 있다.
PCT/KR2017/012651 2016-11-09 2017-11-09 Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 WO2018088813A2 (ko)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP21154441.6A EP3835311B1 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
CN201780069569.5A CN110036023B (zh) 2016-11-09 2017-11-09 Nkx3.2片段和包含其作为活性成分的药物组合物
US16/348,540 US11235025B2 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
CA3042186A CA3042186C (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
CN202211029784.1A CN115925865A (zh) 2016-11-09 2017-11-09 Nkx3.2片段和包含其作为活性成分的药物组合物
JP2019545223A JP6991593B2 (ja) 2016-11-09 2017-11-09 Ｎｋｘ３．２断片及び活性成分としてＮｋｘ３．２断片を含む医薬組成物
AU2017358282A AU2017358282C1 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP17868981.6A EP3539978B1 (en) 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
US16/805,370 US11154590B2 (en) 2016-11-09 2020-02-28 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
AU2020207879A AU2020207879B2 (en) 2016-11-09 2020-07-24 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160149090 2016-11-09
KR10-2016-0149090 2016-11-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/348,540 A-371-Of-International US11235025B2 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
US16/805,370 Division US11154590B2 (en) 2016-11-09 2020-02-28 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient

Publications (3)

Publication Number Publication Date
WO2018088813A2 WO2018088813A2 (ko) 2018-05-17
WO2018088813A3 true WO2018088813A3 (ko) 2018-10-04
WO2018088813A9 WO2018088813A9 (ko) 2018-11-15

Family

ID=62110655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012651 WO2018088813A2 (ko) 2016-11-09 2017-11-09 Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물

Country Status (9)

Country Link
US (2) US11235025B2 (ko)
EP (1) EP3835311B1 (ko)
JP (2) JP6991593B2 (ko)
KR (4) KR102049987B1 (ko)
CN (2) CN115925865A (ko)
AU (2) AU2017358282C1 (ko)
CA (1) CA3042186C (ko)
ES (1) ES2987020T3 (ko)
WO (1) WO2018088813A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060947A1 (fr) * 2016-12-28 2018-06-29 Ynsect Procede de traitement d'insectes comprenant la separation des cuticules de la partie molle des insectes puis la separation de la partie molle en trois fractions
CN112739370B (zh) * 2018-10-19 2024-06-11 Icm株式会社 包含nkx3.2及其片段作为活性成分的治疗视网膜疾病的药物组合物
CN111100195B (zh) * 2018-10-25 2024-04-09 安尼根有限公司 buforin衍生物及其用途
CN112409454B (zh) * 2020-11-04 2022-07-05 青岛农业大学 一种法氏囊七肽及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101150900B1 (ko) * 2010-01-26 2012-05-30 연세대학교 산학협력단 퇴행성 관절염 치료 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO2011028945A1 (en) * 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011093647A2 (en) 2010-01-26 2011-08-04 Industry-Academic Cooperation Foundation, Yonsei University Genes implicated in osteoarthritis and use thereof
KR101150990B1 (ko) 2010-06-19 2012-06-13 김유정 슬롯리스 고정자를 갖는 브러시리스 직류 모터
WO2012097057A2 (en) 2011-01-11 2012-07-19 Tufts University Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
DK3007729T3 (da) * 2013-06-11 2019-09-30 Portage Pharmaceuticals Ltd Struktur, fremstilling og anvendelser af humanderiverede cellegennemtrængelige peptider, der er konjugeret med specifikke biologisk aktive cargo-peptider
WO2018194423A1 (ko) 2017-04-21 2018-10-25 아이씨엠 주식회사 Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101150900B1 (ko) * 2010-01-26 2012-05-30 연세대학교 산학협력단 퇴행성 관절염 치료 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARON, M. M. J. ET AL.: "BAPX-1/NKX-3.2 Acts as a Chondrocyte Hypertrophy Molecular Switch in Osteoarthritis", ARTHRITIS & RHEUMATOLOGY, vol. 67, no. 11, 2015, pages 2944 - 2956, XP055557946 *
DATABASE Protein [O] 6 October 2016 (2016-10-06), XP055557941, retrieved from NCBI Database accession no. NP_001 180.1 *
KIM, J.-A. ET AL.: "Suppression of Nkx3.2 by Phosphatidy linositol-3-kinase Signaling Regulates Cartilage Development by Modulating Chondrocyte Hypertrophy", CELLULAR SIGNALLING, vol. 27, 2015, pages 2389 - 2400, XP029347717 *
PARK, M. ET AL.: "Constitutive RelA Activation Mediated by Nkx3.2 Controls Chondrocyte Viability", NATURE CELL BIOLOGY, vol. 9, no. 3, 2007, pages 287 - 298, XP055557953 *

Also Published As

Publication number Publication date
JP7055455B2 (ja) 2022-04-18
CA3042186A1 (en) 2018-05-17
US20190351015A1 (en) 2019-11-21
CN110036023A (zh) 2019-07-19
JP2019535310A (ja) 2019-12-12
WO2018088813A9 (ko) 2018-11-15
EP3835311A1 (en) 2021-06-16
KR102340761B1 (ko) 2021-12-21
AU2020207879A1 (en) 2020-08-13
KR102049987B1 (ko) 2019-11-28
KR102049978B1 (ko) 2019-11-28
CN110036023B (zh) 2023-01-10
KR20180052104A (ko) 2018-05-17
AU2017358282B2 (en) 2020-07-30
CA3042186C (en) 2021-06-15
EP3539978A4 (en) 2020-08-05
US20200188480A1 (en) 2020-06-18
KR102342171B1 (ko) 2021-12-23
EP3835311C0 (en) 2024-08-28
KR20190126753A (ko) 2019-11-12
JP6991593B2 (ja) 2022-01-12
AU2020207879B2 (en) 2021-04-15
JP2021020962A (ja) 2021-02-18
KR20180052103A (ko) 2018-05-17
AU2017358282A1 (en) 2019-05-23
KR20200129068A (ko) 2020-11-17
ES2987020T3 (es) 2024-11-13
US11235025B2 (en) 2022-02-01
EP3835311B1 (en) 2024-08-28
AU2017358282C1 (en) 2020-11-26
US11154590B2 (en) 2021-10-26
CN115925865A (zh) 2023-04-07
EP3539978A2 (en) 2019-09-18
WO2018088813A2 (ko) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2020006595A (es) Oxadiazoles fungicidas.
EP4438132A3 (en) Stable microcapsule compositions
MX2016013708A (es) Composiciones detergentes de dosis unitaria.
UA116146C2 (uk) Фунгіцидні суміші і, які містять фунгіциди стробілуринового типу
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
WO2015189346A8 (de) Neue stoffmischung zur verbesserung des süssgeschmacks enthaltend rubusosid oder alpha-glycosylrubusosid
PH12017501645B1 (en) Sweetener composition and food containing same
MX2017011711A (es) Mejora en o con relacion a compuestos organicos.
WO2018088813A3 (ko) Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물
MX2016003482A (es) Composiciones antimicrobianas.
WO2017087912A3 (en) Ratiometric biosensors and non-geometrically modulated fret
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MX2016013575A (es) Composicion para prevenir o tratar enfermedades del higado graso.
EP3421041A4 (en) COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISORDERS COMPRISING EXOPOLYSACCHARIDE PRODUCING LEUCONOSTOC MESENTEROIDES AS ACTIVE INGREDIENTS
EP3694331A4 (en) INDAZOLYL-SPIRO [2,3] HEXANCARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2015173427A3 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
MX2018002595A (es) Mezclas biocidas.
WO2016099055A3 (ko) 상심자 및 복령피 혼합 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물
CA2904166C (en) Formulations with reduced oxidation
WO2015003082A3 (en) Volatile organic compound formulations having antimicrobial activity
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
MX2017006476A (es) Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.
WO2019118727A3 (en) Rescue of the pathology of lrrk2 on lysosmes with snx25 or snx27

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17868981

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3042186

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019545223

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017358282

Country of ref document: AU

Date of ref document: 20171109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017868981

Country of ref document: EP

Effective date: 20190611